JP2025504419A5 - - Google Patents
Info
- Publication number
- JP2025504419A5 JP2025504419A5 JP2024541905A JP2024541905A JP2025504419A5 JP 2025504419 A5 JP2025504419 A5 JP 2025504419A5 JP 2024541905 A JP2024541905 A JP 2024541905A JP 2024541905 A JP2024541905 A JP 2024541905A JP 2025504419 A5 JP2025504419 A5 JP 2025504419A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- approximately
- ligand
- groups
- histidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210093514 | 2022-01-26 | ||
| CN202210093514.0 | 2022-01-26 | ||
| PCT/CN2023/073047 WO2023143347A1 (zh) | 2022-01-26 | 2023-01-19 | 一种包含抗CD79b抗体药物偶联物的药物组合物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025504419A JP2025504419A (ja) | 2025-02-12 |
| JP2025504419A5 true JP2025504419A5 (https=) | 2026-01-27 |
Family
ID=87470785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024541905A Pending JP2025504419A (ja) | 2022-01-26 | 2023-01-19 | 抗ＣＤ７９ｂ抗体薬物複合体を含む医薬組成物及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250108122A1 (https=) |
| EP (1) | EP4470568A4 (https=) |
| JP (1) | JP2025504419A (https=) |
| KR (1) | KR20240135622A (https=) |
| CN (1) | CN118382463A (https=) |
| AU (1) | AU2023212240A1 (https=) |
| CA (1) | CA3248952A1 (https=) |
| MX (1) | MX2024009079A (https=) |
| TW (1) | TW202334207A (https=) |
| WO (1) | WO2023143347A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025162364A1 (zh) * | 2024-02-02 | 2025-08-07 | 江苏恒瑞医药股份有限公司 | 抗CD79b抗体药物偶联物联合免疫治疗剂、化疗剂治疗肿瘤 |
| CN121401438A (zh) * | 2024-07-26 | 2026-01-27 | 英诺湖医药(杭州)有限公司 | 一种抗b7h3抗体-艾瑞布林偶联物制剂及其制备方法和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| AU2018320470B2 (en) * | 2017-08-23 | 2025-04-24 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate preparation and lyophilization for same |
| CR20250325A (es) * | 2018-04-13 | 2025-08-29 | Genentech Inc | Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550) |
| WO2020063676A1 (zh) | 2018-09-26 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 依喜替康类似物的配体-药物偶联物及其制备方法和应用 |
| CA3114474A1 (en) | 2018-09-30 | 2020-04-02 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof |
| CN113286823B (zh) | 2019-01-28 | 2024-05-07 | 上海拓界生物医药科技有限公司 | 抗cd79b抗体、其抗原结合片段及其医药用途 |
| CN111939267B (zh) * | 2019-05-17 | 2024-12-20 | 百奥泰生物制药股份有限公司 | 抗体-药物偶联物制剂、制备方法及应用 |
| CN113116812A (zh) * | 2019-12-30 | 2021-07-16 | 百奥泰生物制药股份有限公司 | 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用 |
| JP7821733B2 (ja) * | 2020-01-22 | 2026-02-27 | 上海森輝医薬有限公司 | エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用 |
| BR112022019073A2 (pt) * | 2020-03-25 | 2022-11-08 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma |
| TWI888610B (zh) * | 2020-07-27 | 2025-07-01 | 大陸商上海拓界生物醫藥科技有限公司 | 抗ｃｄ７９ｂ抗體藥物偶聯物、其製備方法及其醫藥用途 |
-
2023
- 2023-01-19 JP JP2024541905A patent/JP2025504419A/ja active Pending
- 2023-01-19 CN CN202380015150.7A patent/CN118382463A/zh active Pending
- 2023-01-19 TW TW112102807A patent/TW202334207A/zh unknown
- 2023-01-19 WO PCT/CN2023/073047 patent/WO2023143347A1/zh not_active Ceased
- 2023-01-19 CA CA3248952A patent/CA3248952A1/en active Pending
- 2023-01-19 MX MX2024009079A patent/MX2024009079A/es unknown
- 2023-01-19 AU AU2023212240A patent/AU2023212240A1/en active Pending
- 2023-01-19 KR KR1020247026056A patent/KR20240135622A/ko active Pending
- 2023-01-19 US US18/832,908 patent/US20250108122A1/en active Pending
- 2023-01-19 EP EP23746228.8A patent/EP4470568A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102397713B1 (ko) | 안정한 액체 약제학적 제제 | |
| KR101782301B1 (ko) | 항-ｃｄ20 항체를 포함하는 고농축 약제 | |
| JP2025504419A5 (https=) | ||
| AU2025208451A1 (en) | Antibody-drug conjugate preparation and lyophilization for same | |
| US20140227250A1 (en) | Stable formulations of antibodies to tslp | |
| JP2021517129A5 (https=) | ||
| JP2020510671A5 (https=) | ||
| JP2022036932A5 (https=) | ||
| FI3618863T3 (fi) | Anti-TIGIT-vasta-aineita ja menetelmiä niiden käyttämiseksi | |
| CN111065411A (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| TW201813667A (zh) | 一種抗ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合在製備治療癌症的藥物中的用途 | |
| CN102961745B (zh) | 抗体组合物制剂及其应用 | |
| JP2018500380A (ja) | アグリコシル化治療用抗体の製剤 | |
| CN116096896A (zh) | 一种含抗体药物偶联物的药物组合物及其用途 | |
| TW202330040A (zh) | 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP2023554087A5 (https=) | ||
| JP2024505556A (ja) | がん、腫瘍および腫瘍細胞の局所および全身処置のための方法 | |
| CN119424632A (zh) | 治疗结直肠癌的联用药物组合物 | |
| KR20220129532A (ko) | 중합체성 약물 전달 콘주게이트와 이의 제조 및 사용 방법 | |
| JP2023553538A5 (https=) | ||
| TW202019466A (zh) | 包含掩蔽的抗原結合蛋白質之配製物及藥物組成物 | |
| RU2020111574A (ru) | Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом | |
| JP2022518441A5 (https=) | ||
| TW202034925A (zh) | Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途 | |
| RU2024123714A (ru) | Фармацевтическая композиция, содержащая конъюгат анти-cd79b антитело-лекарственное средство, и ее применение |